TD Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

TD Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-67,500	Closed	-$257K	–	1453
2020 Q1	$257K	Sell	67,500 -29,500	-30%	-$127K	﹤0.01%	1289
2019 Q4	$494K	Sell	97,000 -6,800	-7%	-$36K	﹤0.01%	1246
2019 Q3	$525K	Buy	103,800 +61,370	+145%	+$306K	﹤0.01%	1162
2019 Q2	$262K	Buy	+42,430	New	+$205K	﹤0.01%	1266

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

TD Asset Management's PGNX Position: Q2 2020 in Review

TD Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 67,500 shares — an estimated $257K sold.

TD Asset Management first reported a position in PGNX in Q2 2019 and held it in 4 quarters. The position peaked at $525K in Q3 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

TD Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
TD Asset Management sold 67,500 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $257K.
TD Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q2 2019 and held it in 4 quarters.
TD Asset Management's Progenics Pharmaceuticals Inc position peaked at $525K in Q3 2019.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on TD Asset Management's 13F filing for Q2 2020, filed 13 Aug 2020.